What is the current high-teens, low 20% range for the company's growth 
h being in the high-teens, low 20% range. Is that still intact? Which new markets are you planning to launch it in 2021? I heard five new markets in the prepared remarks. And how far behind is Omnipod 5 outside the U.S. compared to the U.S.? And I had one follow-up.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
Great. Maybe I'll ask Wayde to give a little bit of insight into the overall expectations for international growth. There is nothing fundamental in the business that would change our long-term expectations for that business. It's just simply that we're in the midst of a pandemic and that there has been a slower recovery in particularly Europe and other parts of the world and particularly the United States. So we remain very bullish on our expansion strategy over the long-term. And that's why I mentioned in my remarks that we're really starting in earnest our expansion in early 2021. And over time, this adds significant addressable market to us over the coming years. We didn't give the five markets, so we'll lay those out for you as we enter into them. We did get one checked off the box this quarter in Belgium. So actually, one of the five we just entered. And we will let you know as we enter these markets that those launches have occurred.
And then you had also asked, Larry, about Omnipod 5 in international. We haven't given a timeline on that yet. Just to let everybody know that that work is under way and we are fully committed to bringing Omnipod 5 to our European markets and to all of our international markets.
Larry Biegelsen -- Wells Fargo -- Analyst
Thank you. And on Omnipod 5, do you guys typically announce when you have filed or submitted something like that? And is there any reason why the pivotal Omnipod 5 data would look much different from the pre-pivotal data we saw at ADA this year. For example, larger number of centers, anything that we should be aware of that would make that data, the pivotal data look meaningfully different from the pre-pivotal data that we should be aware of? Thanks for taking the questions.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
Sure. Thanks, Larry. And we don't -- our practice is not to notify or become public when we submit. We simply share the news when we're cleared. So that's our general practice. In terms of the data, I really don't have much insight to offer there. We don't want to preview it. Obviously, the pre-pivotal data look very, very strong and we are very excited to get the Omnipod pivotal data out there. But I don't want to give insight into just how it compares at this point.
Larry Biegelsen -- Wells Fargo -- Analyst
Understood. Thank you.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
Thanks, Larry.
Operator
Thank you. Our next question comes from the line of Jeff Johnson from Baird. Please go ahead.
Jeff Johnson -- Robert W. Baird & Co. -- Analyst
Thank you. Good afternoon, guys. Maybe just a couple of clarifying questions. Wayde, you mentioned Omnipod 5 pricing and thoughts on a premium potentially for next year. I thought that was kind of settled at this point that you probably were going to go after access more than pricing just to try to get it out there faster and even more broadly across accounts in that. So just -- is there being -- is there a reconsideration happening that maybe you could get a premium for O5 or how to think about that?
Wayde McMillan -- Executive Vice President, Chief Financial Officer and Treasurer
Yeah. It's still a question for us, Jeff. And there is a lot of different opportunities for us across the U.S. in particular. But like you said, a major consideration for us is getting us out to our customers as fast as possible. And we certainly take into consideration the current environment that we're in other AID systems that are in the marketplace and we also know that there is a significant opportunity for us 
h being in the high-teens, low 20% range. Is that still intact? Which new markets are you planning to launch it in 2021? I heard five new markets in the prepared remarks. And how far behind is Omnipod 5 outside the U.S. compared to the U.S.? And I had one follow-up.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
Great. Maybe I'll ask Wayde to give a little bit of insight into the overall expectations for international growth. There is nothing fundamental in the business that would change our long-term expectations for that business. It's just simply that we're in the midst of a pandemic and that there has been a slower recovery in particularly Europe and other parts of the world and particularly the United States. So we remain very bullish on our expansion strategy over the long-term. And that's why I mentioned in my remarks that we're really starting in earnest our expansion in early 2021. And over time, this adds significant addressable market to us over the coming years. We didn't give the five markets, so we'll lay those out for you as we enter into them. We did get one checked off the box this quarter in Belgium. So actually, one of the five we just entered. And we will let you know as we enter these markets that those launches have occurred.
And then you had also asked, Larry, about Omnipod 5 in international. We haven't given a timeline on that yet. Just to let everybody know that that work is under way and we are fully committed to bringing Omnipod 5 to our European markets and to all of our international markets.
Larry Biegelsen -- Wells Fargo -- Analyst
Thank you. And on Omnipod 5, do you guys typically announce when you have filed or submitted something like that? And is there any reason why the pivotal Omnipod 5 data would look much different from the pre-pivotal data we saw at ADA this year. For example, larger number of centers, anything that we should be aware of that would make that data, the pivotal data look meaningfully different from the pre-pivotal data that we should be aware of? Thanks for taking the questions.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
 Sure. Thanks, Larry. And we don't -- our practice is not to notify or become public when we submit. We simply share the news when we're cleared. So that's our general practice. In terms of the data, I really don't have much insight to offer there. We don't want to preview it. Obviously, the pre-pivotal data look very, very strong and we are very excited to get the Omnipod pivotal data out there. But I don't want to give insight into just how it compares at this point.
Larry Biegelsen -- Wells Fargo -- Analyst
Understood. Thank you.
Shacey Petrovic -- Director, President and Chief Executive Officer of Insulet Corporation and Director, Exact Sciences 
Thanks, Larry.
Operator
Thank you. Our next question comes from the line of Jeff Johnson from Baird. Please go ahead.
Jeff Johnson -- Robert W. Baird & Co. -- Analyst
Thank you. Good afternoon, guys. Maybe just a couple of clarifying questions. Wayde, you mentioned Omnipod 5 pricing and thoughts on a premium potentially for next year. I thought that was kind of settled at this point that you probably were going to go after access more than pricing just to try to get it out there faster and even more broadly across accounts in that. So just -- is there being -- is there a reconsideration happening that maybe you could get a premium for O5 or how to think about that?
Wayde McMillan -- Executive Vice President, Chief Financial Officer and Treasurer
Yeah. It's still a question for us, Jeff. And there is a lot of different opportunities for us across the U.S. in particular. But like you said, a major consideration for us is getting us out to our customers as fast as possible. And we certainly take into consideration the current environment that we're in other AID systems that are in the marketplace and we also know that there is a significant opportunity for us 